Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
6Customers
2Debt Items
12Related Chains
Source-Backed Evidence Depth
Prelude Therapeutics Incorporated (PRLD) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
3Distinct source URLs
9High confidence
0.838Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Prelude Therapeutics Incorporated Suppliers
Ticker
Name
Confidence
Evidence
JEFFERIES-LLC
JEFFERIES-LLC
92%
In accordance with the terms of the Sales Agreement, on March 12, 2026, the Company filed a prospectus supplement...pursuant to which the Company may offer and sell up to $25.0 million of its Common …
PATHOS-AI-INC
PATHOS-AI-INC
90%
Pathos will pay us milestone payments upon the achievement of specified development and sales milestone events, as well as royalties on sales of the licensed products.
Reciprocal relationship from INCY graph: Reciprocal relationship from PRLD graph: Reciprocal relationship from INCY graph: Reciprocal relationship from PRLD graph: Reciprocal relationship from INCY g…
Prelude Therapeutics Incorporated Customers
Ticker
Name
Confidence
Evidence
ABCELLERA-BIOLOGICS-INCORPORATED
ABCELLERA-BIOLOGICS-INCORPORATED
92%
Under the terms of the agreement, AbCellera will lead manufacturing activities and the Company will lead clinical development and global commercialization
ABCELLERA
ABCELLERA
90%
We received an upfront non-refundable payment from AbCellera of $6.5 million in the third quarter of 2025 upon signing the Amended Agreement and an upfront non-refundable payment of $6 million in Oct…
PATHOS-AI-INC
PATHOS-AI-INC
90%
The Company granted to Pathos an exclusive, sublicensable, world-wide license to its selective, brain-penetrant PRMT5 inhibitor, PRT811
INCYTE
INCYTE
85%
the Company entered into a securities purchase agreement with Incyte (the "Securities Purchase Agreement"), pursuant to which Incyte purchased 6,250,000 shares of the Company's non-voting common stock
K-SMALLER-REPORTING-COMPANY
K-SMALLER-REPORTING-COMPANY
62%
any products for several years, if at all. At March 31, 2026 the Company had cash, cash equivalents, restricted cash and marketable securities totaling $84.8 million. Subsequent to March 31, 2026, th…
RECENTLY-ISSUED-ACCOUNTING-PRONOUNCEMENTS-EMERGI
RECENTLY-ISSUED-ACCOUNTING-PRONOUNCEMENTS-EMERGI
62%
d vendors based upon estimates of the proportion of work completed. These estimates are determined by reviewing contracts, vendor agreements and purchase orders, and through discussions with internal…
